United KingdomAdd to My Companies | Give a Referral for this Company | Print this Profile
Partnership and licensing opportunities from Abzena Plc.
Abzena has over 40 technology licence and option agreements covering its proprietary antibody drug conjugate (ADC) linker, antibody humanisation, and protein deimmunisation technologies.
The linker technology produces more stable and homogenous ADCs and the humanisation and deimmunisation technologies reduce the risk of therapeutic antibodies and other proteins producing an unwanted effect in patients.
There are currently twelve therapeutic antibodies produced using Abzena’s antibody humanisation technology being progressed through clinical development by its partners.
This is the Partnership and Licensing section of the company profile page for Abzena Plc on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.